ACP
BMRN icon

Altitude Crest Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

Altitude Crest Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-114,042
Closed -$11M – 32
2023
Q4 		$11M Buy
+114,042
New +$10.1M 7.36% 5

Other funds holding BMRN

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Altitude Crest Partners's BMRN Position: Q1 2024 in Review

Altitude Crest Partners sold out of BioMarin Pharmaceuticals (BMRN) in Q1 2024, closing a stake of 114,042 shares — an estimated $11M sold.

Altitude Crest Partners first reported a position in BMRN in Q4 2023 and held it in 1 quarter. The position peaked at $11M in Q4 2023. 560 funds tracked by Wall St. Rank hold BMRN as of Q1 2024.

  • Altitude Crest Partners reported no remaining BioMarin Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 114,042 BioMarin Pharmaceuticals shares in Q1 2024, an estimated $11M.
  • Altitude Crest Partners first reported a position in BioMarin Pharmaceuticals in Q4 2023 and held it in 1 quarter.
  • Altitude Crest Partners's BioMarin Pharmaceuticals position peaked at $11M in Q4 2023.
  • 560 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2024.

Based on Altitude Crest Partners's 13F filing for Q1 2024, filed 14 May 2024.